JP5087551B2 - 脈管の損傷を修復するための組成物および方法 - Google Patents

脈管の損傷を修復するための組成物および方法 Download PDF

Info

Publication number
JP5087551B2
JP5087551B2 JP2008540041A JP2008540041A JP5087551B2 JP 5087551 B2 JP5087551 B2 JP 5087551B2 JP 2008540041 A JP2008540041 A JP 2008540041A JP 2008540041 A JP2008540041 A JP 2008540041A JP 5087551 B2 JP5087551 B2 JP 5087551B2
Authority
JP
Japan
Prior art keywords
cells
composition
cxcr
catheter
cell product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008540041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009514950A5 (https=
JP2009514950A (ja
Inventor
ロバート エイ プレティ
アンドリュー エル ペコラ
Original Assignee
アモーサイト インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アモーサイト インコーポレイテッド filed Critical アモーサイト インコーポレイテッド
Publication of JP2009514950A publication Critical patent/JP2009514950A/ja
Publication of JP2009514950A5 publication Critical patent/JP2009514950A5/ja
Application granted granted Critical
Publication of JP5087551B2 publication Critical patent/JP5087551B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
JP2008540041A 2005-11-07 2006-10-24 脈管の損傷を修復するための組成物および方法 Expired - Fee Related JP5087551B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73415105P 2005-11-07 2005-11-07
US60/734,151 2005-11-07
PCT/US2006/041536 WO2007055905A2 (en) 2005-11-07 2006-10-24 Compositions and methods of vascular injury repair

Publications (3)

Publication Number Publication Date
JP2009514950A JP2009514950A (ja) 2009-04-09
JP2009514950A5 JP2009514950A5 (https=) 2011-05-06
JP5087551B2 true JP5087551B2 (ja) 2012-12-05

Family

ID=38023762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008540041A Expired - Fee Related JP5087551B2 (ja) 2005-11-07 2006-10-24 脈管の損傷を修復するための組成物および方法

Country Status (13)

Country Link
US (2) US7794705B2 (https=)
EP (2) EP1951864B1 (https=)
JP (1) JP5087551B2 (https=)
CA (1) CA2628712C (https=)
DK (2) DK1951864T3 (https=)
ES (2) ES2486300T4 (https=)
IL (2) IL191277A (https=)
MY (1) MY147516A (https=)
PL (2) PL2441461T3 (https=)
PT (2) PT2441461E (https=)
SI (2) SI2441461T1 (https=)
WO (1) WO2007055905A2 (https=)
ZA (1) ZA200804711B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
WO2008056368A2 (en) * 2006-11-09 2008-05-15 Gamida-Cell Ltd. Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
US8137968B2 (en) * 2007-02-28 2012-03-20 The Board Of Trustees Of The University Of Illinois Selected endothelial progenitor cells and methods for use
BRPI0919020B8 (pt) * 2008-09-12 2021-05-25 Cryopraxis Criobiologia Ltda uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
CN102245189B (zh) * 2008-12-03 2015-06-17 阿莫塞特公司 改善梗死区灌注的组合物以及血管损伤修复方法
JP5709880B2 (ja) * 2009-10-23 2015-04-30 アモーサイト インコーポレイテッド 血管の機能不全による進行性心筋傷害治療のための組成物および方法
US9533010B2 (en) 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
EP2943206A4 (en) * 2013-01-12 2017-01-04 Cesca Therapeutics Inc. Rapid infusion of autologous bone marrow derived stem cells
ES2927175T3 (es) 2013-02-12 2022-11-03 Reneuron Ltd Método de producción de micropartículas
US20140313321A1 (en) 2013-02-13 2014-10-23 SeeScan, Inc. Optical ground tracking apparatus, systems, and methods
WO2016006782A1 (ko) * 2014-07-08 2016-01-14 라정찬 줄기세포의 보관 안정성 증진용 조성물
US11504335B2 (en) 2018-06-18 2022-11-22 University Of Kentucky Research Foundation Increased cell retention in diseased site when cells encapsulated in gelatin methacrylate and polyethylene glycol diacrylate hydrogels
WO2020154664A1 (en) * 2019-01-25 2020-07-30 The Johns Hopkins University Predicting atrial fibrillation recurrence after pulmonary vein isolation using simulations of patient-specific magnetic resonance imaging models and machine learning
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
EP4228406A4 (en) 2020-10-14 2024-11-13 Ossium Health, Inc. SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION
CN117279650A (zh) 2020-12-18 2023-12-22 奥瑟姆健康公司 细胞治疗方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055556A (en) 1981-10-06 1991-10-08 The Board Of Trustees Of The Leland Stanford Jr. Univ. Fluorescent conjugates for analysis of molecules and cells
US4859582A (en) 1981-10-06 1989-08-22 The Board Of Trustees Of The Leland Stanford Jr. University Fluorescent conjugates for analysis of molecules and cells
US4520110A (en) 1981-10-06 1985-05-28 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing a phycobiliprotein labeled ligand or receptor
EP0076695B1 (en) 1981-10-06 1985-02-20 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent conjugates for analysis of molecules and cells
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US5656493A (en) 1985-03-28 1997-08-12 The Perkin-Elmer Corporation System for automated performance of the polymerase chain reaction
US5333675C1 (en) 1986-02-25 2001-05-01 Perkin Elmer Corp Apparatus and method for performing automated amplification of nucleic acid sequences and assays using heating and cooling steps
FR2596413B1 (fr) 1986-03-27 1988-06-10 Merieux Inst Nouveaux milieux de culture de bacteries appartenant au genre bordetella, contenant des derives etherifies de polymeres de d-glucose, et leur application
US5627027A (en) 1986-04-18 1997-05-06 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US5569587A (en) 1986-04-18 1996-10-29 Carnegie Mellon University Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes
US4876190A (en) 1987-10-21 1989-10-24 Becton Dickinson & Company Peridinin-chlorophyll complex as fluorescent label
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5723218A (en) 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
US5726152A (en) 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
US5234824A (en) 1990-11-13 1993-08-10 Specialty Laboratories, Inc. Rapid purification of DNA
US5187083A (en) 1990-11-13 1993-02-16 Specialty Laboratories, Inc. Rapid purification of DNA
DE69229454T2 (de) 1991-03-28 2000-01-05 Merck & Co., Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5776709A (en) 1991-08-28 1998-07-07 Becton Dickinson And Company Method for preparation and analysis of leukocytes in whole blood
WO1993025216A1 (en) 1992-06-08 1993-12-23 Becton, Dickinson And Company Human primitive stem cells
CA2170357A1 (en) 1993-08-25 1995-03-02 David Digiusto Method for producing a highly enriched population of hematopoietic stem cells
US5415636A (en) 1994-04-13 1995-05-16 Schneider (Usa) Inc Dilation-drug delivery catheter
US5968753A (en) 1994-06-14 1999-10-19 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US20030113304A1 (en) 1995-06-07 2003-06-19 The Trustees Of Columbia University Selective tissue site revascularization by combined focal injury and hematopoietic stem cell introduction
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US8075880B2 (en) 1999-01-11 2011-12-13 Steward St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for regulating angiogenesis
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
CA2311729A1 (en) 1998-01-23 1999-07-29 Imclone Systems Incorporated Purified populations of stem cells
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US7115417B1 (en) 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
CA2330208A1 (en) 1998-05-29 1999-12-02 Thomas Jefferson University Compositions and methods for use in affecting hematopoietic stem cell populations in mammals
IL125532A0 (en) 1998-07-27 1999-03-12 Yeda Res & Dev Hematopoietic cell composition for use in transplantation
CA2341754A1 (en) 1998-08-31 2000-03-09 New York University Stem cells bearing an fgf receptor on the cell surface
US6287265B1 (en) * 1999-06-23 2001-09-11 Cindy L. Gleason Blood collection kit
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
AU1100001A (en) 1999-10-29 2001-05-14 Children's Hospital Of Los Angeles Gammac negative hematopoietic progenitor cells
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
AU2001250966A1 (en) 2000-03-23 2001-10-03 Stem Cells, Inc. Pluripotential stem cells
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US6878371B2 (en) * 2000-07-26 2005-04-12 Boston Scientific Scimed, Inc. Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
WO2002013760A2 (en) 2000-07-31 2002-02-21 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
AU2001284695A1 (en) 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
CA2421834A1 (en) 2000-09-11 2002-03-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Use of carp inhibitors for the treatment of heart diseases
JP2005508831A (ja) 2000-10-02 2005-04-07 ザ スクリプス リサーチ インスティテュート 血管新生促進のための方法および組成物
FR2819265B1 (fr) 2001-01-10 2004-01-02 Centre Nat Rech Scient Cellules du tissu adipeux extramedullaire et leurs applications dans la reconstitution des lignees hematopoietiques
EP1361896A2 (en) 2001-01-23 2003-11-19 Boston Scientific Corporation Localized myocardial injection method for treating ischemic myocardium
JP2004536794A (ja) 2001-04-09 2004-12-09 メドトロニック、インコーポレイテッド マイクロ遠心機を用いる血液成分の分離方法及びその使用法
ITTO20010517A1 (it) 2001-05-31 2002-12-01 Giulio Alessandri Cellule progenitrici vascolari umane.
WO2003013570A1 (en) 2001-08-09 2003-02-20 Cornell Research Foundation, Inc. Platelet-derived growth factor protection of cardiac myocardium
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
AU2002353465B2 (en) * 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
EP1465983B1 (en) 2001-12-21 2010-03-31 Immunex Corporation Endothelial stem cells, populations, methods of isolation and use thereof
AU2003217271A1 (en) 2002-01-29 2003-09-02 A. Mark Colb Endothelialization of vascular surfaces
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
EP1551955A4 (en) 2002-07-16 2006-11-29 Yissum Res Dev Co METHOD FOR IMPLANTING MESENCHYMAL STEM CELLS FOR TISSUE PAIRING AND FORMATION
PL216193B1 (pl) 2002-07-25 2014-03-31 Scripps Research Inst Wyizolowana, ssacza, pochodząca ze szpiku kostnego linia populacji niezróżnicowanych krwiotwórczych komórek macierzystych
AU2003270051A1 (en) 2002-08-29 2004-03-19 Baylor College Of Medicine Heart derived cells for cardiac repair
US9969977B2 (en) 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US20040136973A1 (en) 2002-11-07 2004-07-15 Eliezer Huberman Human stem cell materials and methods
WO2004052177A2 (en) 2002-12-05 2004-06-24 Case Western Reserve University Cell-based therapies for ischemia
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
US6995087B2 (en) * 2002-12-23 2006-02-07 Chartered Semiconductor Manufacturing Ltd. Integrated circuit with simultaneous fabrication of dual damascene via and trench
US20040197310A1 (en) 2003-02-12 2004-10-07 Sanberg Paul R. Compositions and methods for using umbilical cord progenitor cells in the treatment of myocardial infarction
CN1770976A (zh) 2003-02-13 2006-05-10 人类起源公司 利用脐带血治疗患有疾病、紊乱或状况的个体的用途
US7863043B2 (en) 2004-02-11 2011-01-04 Aldagen, Inc. Stem cell populations and methods of use
US20050232905A1 (en) 2004-03-26 2005-10-20 Yeh Edward T Use of peripheral blood cells for cardiac regeneration
US7910755B2 (en) 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
JP2006115771A (ja) 2004-10-22 2006-05-11 Kyoto Univ 骨格筋由来の心筋幹細胞
WO2006093860A2 (en) 2005-02-28 2006-09-08 Regenetech, Inc. Method and composition for repairing heart tissue
WO2006121532A2 (en) 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease

Also Published As

Publication number Publication date
EP1951864A4 (en) 2009-04-29
ES2485387T3 (es) 2014-08-13
EP1951864A2 (en) 2008-08-06
PT1951864E (pt) 2014-08-27
ZA200804711B (en) 2009-10-28
PT2441461E (pt) 2014-08-26
MY147516A (en) 2012-12-31
CA2628712A1 (en) 2007-05-18
IL232997A (en) 2016-06-30
DK1951864T3 (da) 2014-07-28
EP2441461A1 (en) 2012-04-18
US20090226402A1 (en) 2009-09-10
PL2441461T3 (pl) 2014-11-28
EP1951864B1 (en) 2014-05-07
US20070105217A1 (en) 2007-05-10
JP2009514950A (ja) 2009-04-09
US7794705B2 (en) 2010-09-14
SI1951864T1 (sl) 2014-09-30
US8088370B2 (en) 2012-01-03
PL1951864T3 (pl) 2014-10-31
EP2441461B1 (en) 2014-05-07
DK2441461T3 (da) 2014-07-28
IL191277A (en) 2014-06-30
ES2486300T3 (es) 2014-08-18
CA2628712C (en) 2014-02-11
WO2007055905A2 (en) 2007-05-18
WO2007055905A3 (en) 2007-07-12
SI2441461T1 (sl) 2014-09-30
IL232997A0 (en) 2014-07-31
ES2486300T4 (es) 2020-05-25

Similar Documents

Publication Publication Date Title
US8088370B2 (en) Compositions and methods of vascular injury repair
EP2367432B1 (en) Infarct area perfusion-improving composition
US8709403B2 (en) Compositions and methods of vascular injury repair
US8425899B2 (en) Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
EP3170891B1 (en) Compositions and uses for treating progressive myocardial injury due to a vascular insufficiency
HK1169327B (en) Compositions and methods of vascular injury repair
HK1169327A (en) Compositions and methods of vascular injury repair
HK1117874A (en) Compositions and methods of vascular injury repair
HK1233305A1 (en) Compositions and uses for treating progressive myocardial injury due to a vascular insufficiency
HK1233305B (en) Compositions and uses for treating progressive myocardial injury due to a vascular insufficiency

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110316

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20110316

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20110413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110816

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120730

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120827

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120910

R150 Certificate of patent or registration of utility model

Ref document number: 5087551

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150914

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

Free format text: JAPANESE INTERMEDIATE CODE: R313111

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees